Domingo Liotta Hospital, Houston, Texas. First Clinical use. 1966 (August 8): Liotta-DeBakey LVAD in a paracorporeal position in cardiogenic shock postcardiotomy, Methodist Hospital, Houston, Texas. First successful clinical use. 1969 (April 4): Liotta-Cooley Total Artificial Heart, Texas Heart Institute, Houston, Texas. First clinical use. http://www.texasheartinstitute.org/Research/Devices/liotta.cfm. This device was stolen from the lab of Dr. Michael E. DeBakey by Liotta. Dr. Cooley was not involved in any way in its development. The device had not been successful in animal experiments, and while the patient had the artificial heart in place he developed multiple system organ failure, as the experimental animals had, and died
Human artificial chromosome by these vectors not only leads to different expression levels, but the inserts also disrupt the original genome. HACs differ in this regard, as they are entirely separate chromosomes. This separation from existing genetic material assumes that no insertional mutants would arise. This stability and accuracy makes HACs preferable to other methods such as viral vectors, YACs and BACs. HACs allow for delivery of more DNA (including promoters and copy-number variation) than is possible with viral vectors. Yeast artificial chromosomes and bacterial artificial chromosomes were created before human artificial chromosomes, which first appeared in 1997. HACs are useful in expression